Gold nanosensor spots difference between dengue, Zika

dengue zika1
Distinguishing between dengue and Zika viruses is complicated because of their genetic similarities. Copyright: Peter Ilicciev/Fundación Oswaldo Cruz (Creative Commons).

Speed read

  • Genetic similarities make spotting differences between dengue and Zika difficult
  • Correct diagnosis essential for patient management, treatment
  • Gold nanosensor test at technological development stage

Send to a friend

The details you provide on this page will not be used to send unsolicited email, and will not be sold to a 3rd party. See privacy policy.

A new class of nanosensor developed in Brazil could more accurately identify dengue and Zika infections, a task that is complicated by their genetic similarities and which can result in misdiagnosis.
The technique uses gold nanoparticles and can “observe” viruses at the atomic level, according to a study published in Scientific Reports (9 July).
Belonging to the Flavivirus genus in the Flaviviridae family, Zika and dengue viruses share more than 50 per cent similarity in their amino acid sequence. Both viruses are spread by mosquitos and can have long-term side effects. The Flaviviridae virus family was named after the yellow fever virus and comes from the Latin word for golden, or yellow, in colour.

“The fact that this test doesn’t require reagents and uses ELISA equipment, which is widely available, is very important because the countries that suffer the most with Zika and dengue are poor.”

Juliana Cortines, Federal University of Rio de Janeiro

“Diagnosing [dengue virus] infections is a high priority in countries affected by annual epidemics of dengue fever. The correct diagnostic is essential for patient managing and prognostic as there are no specific antiviral drugs to treat the infection,” the authors say.
More than 1.8 million people are suspected to have been infected with dengue so far this year in the Americas, with 4000 severe cases and almost 700 deaths, the Pan American Health Organization says. The annual global average is estimated to be between 100 million and 400 million dengue infections, according to the World Health Organization.

A dengue fever outbreak has hit Brazil and other parts of Latin America. Governments have distributed educational materials.
Credit: Raul Santana/Fundación Oswaldo Cruz (Creative Commons license).

Flávio Fonseca, study co-author and researcher at the Federal University of Minas Gerais, tells SciDev.Net it is almost impossible to differentiate between dengue and Zika viruses.
“A serologic test that detects antibodies against dengue also captures Zika-generated antibodies. We call it cross-reactivity,” he says.
Co-author and virologist, Maurício Nogueira, tells SciDev.Net that avoiding cross-reactivity is crucial because “dengue is a disease that kills — and can do so quickly if the right diagnosis is not made. As for Zika, it offers risks for foetuses to develop microcephaly, and we can’t let pregnant women spend seven or eight months wondering whether they have the virus or not.”
There is also no specific antiviral treatment for Zika and the search for a vaccine is ongoing.
Virus differentiation is important to accurately measure the real impact of both diseases on public health. The most widely used blood test, the enzyme-linked immunosorbent assay (ELISA), is limited in its ability to tell the difference between the viruses, the authors say.
As dengue has four variations, known as serotypes, the team created four different nanoparticles and covered each of them with a different dengue protein. They applied ELISA serum and a blood sample. The researchers found that sample antibodies bound with the viruses’ proteins, changing the pattern of electrons on the gold nanoparticle surface.
“We can see this change by applying certain frequencies of light on the nanoparticle’s surface. Dengue proteins absorbed light — Zika ones did not,” Fonseca says. Nogueira, who coordinated the project, adds that the results were important to calibrate the tests with the gold nanoparticles.
Juliana Cortines, a virologist at the Federal University of Rio de Janeiro, who was not involved in the study, is enthusiastic about the results.
“The fact that this test doesn’t require reagents and uses ELISA equipment, which is widely available, is very important because the countries that suffer the most with Zika and dengue are poor,” Cortines tells SciDev.Net.
The study argues that the gold nanoparticle-based test is more precise than other blood antibody tests because of its high sensitivity and capacity to identify which virus has been detected.

Plans to develop the product at an industrial scale have been interrupted by the COVID-19 pandemic, Fonseca says.
The costs are expected to be similar to conventional ELISA tests, he adds, but says better estimates will be possible later in the production process.

“The only drawback,” Cortines adds, “which is also pointed out in the paper, is that although the analysis can be performed quickly, it still has to be done manually.

“It took them time to develop the protocols, but once done, the experiments are quite simple.”

The project, coordinated by Maurício Nogueira, is funded by FAPESP, a donor of SciDev.Net

This piece was produced by SciDev.Net’s Latin America & Caribbean desk.